← Browse by Condition
Medical Condition
astrocytoma grade iii
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 1, Phase 2
NCT06161974 Phase 2
Recruiting
Study of Olutasidenib and Temozolomide in HGG
Enrollment
60 pts
Location
United States, Austr...
Sponsor
Rigel Pharmaceuticals
NCT05765812 Phase 1, Phase 2
Recruiting
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Enrollment
116 pts
Location
United States, Spain...
Sponsor
Debiopharm International SA